MANTLE CELL LYMPHOMA

This study is testing a cancer drug called acalabrutinib for people with mantle cell lymphoma who had to stop a similar drug, ibrutinib, because of severe side effects. The goal is to see if acalabrutinib can control the cancer while being easier for patients to tolerate. Researc…

This study is testing whether a combination of two targeted drugs, ibrutinib and rituximab, can effectively control a slower-growing form of mantle cell lymphoma without using traditional chemotherapy. It is for 50 adults who have been diagnosed but have not yet started any treat…

This trial is testing two different drug combinations for people newly diagnosed with mantle cell lymphoma, a type of blood cancer. It will compare a two-drug regimen (ibrutinib plus an antibody) against a three-drug regimen that adds a medication called venetoclax. The main goal…

This study is testing an experimental pill called BGB-11417 for people with mantle cell lymphoma, a type of blood cancer, that has come back or stopped responding to other treatments. The first part of the study aims to find a safe and effective dose. The second part will see how…

This study is testing whether taking a daily pill called ibrutinib for up to five years can delay the progression of a slow-growing, high-risk form of mantle cell lymphoma in patients who have not yet received any treatment. The goal is to see if this long-term medication can kee…

This study is testing whether specially grown cord blood stem cells can help patients with high-risk blood cancers recover their immune systems faster after a transplant. Participants receive a transplant using these expanded stem cells after strong chemotherapy. Researchers are …

This study is testing whether combining two oral drugs, palbociclib and ibrutinib, can help control mantle cell lymphoma in patients whose cancer has returned or worsened after at least one prior treatment. The main goal is to see how long the combination can keep the cancer from…

This study compares three different drug combinations for people 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. Researchers want to see if adding a newer targeted drug called acalabrutinib to standard chemotherapy works better than chemotherapy a…

This study is testing a new drug called zilovertamab vedotin (MK-2140) for people with several types of advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to see if the drug is safe and if it can shrink or eliminate the…

This is a first-in-human safety study testing a new, experimental CAR-T cell therapy called CAR19.20.22 in adults with B-cell lymphomas that have returned or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, engineered to attack canc…

This early-stage study is testing whether combining two drugs, glofitamab and lenalidomide, is a safe and feasible treatment for adults with mantle cell lymphoma that has come back or stopped responding to other therapies. It is specifically for people whose cancer progressed aft…

This study is testing an experimental drug called iopofosine I 131 in people with various advanced B-cell blood cancers that have come back or stopped responding to standard treatments. The drug is designed to deliver radiation directly to cancer cells. The main goal is to see if…

This study is testing whether a combination of two drugs, acalabrutinib and rituximab, can effectively control mantle cell lymphoma in older adults who have not yet received any treatment. The goal is to see how well this drug pair works to put the cancer into remission and to un…

This large, late-stage trial is for adults with a type of blood cancer called mantle cell lymphoma who are in remission after initial treatment. It aims to find out if adding an intensive stem cell transplant to a standard drug (rituximab) is better at keeping the cancer from com…

This early-stage study aims to find the safest and most effective dose of a three-drug combination (ibrutinib, lenalidomide, and rituximab) for adults with mantle cell lymphoma that has returned or stopped responding to prior treatment. The main goal is to see how much of the new…

This study is testing a new treatment plan for younger adults newly diagnosed with mantle cell lymphoma, a type of blood cancer. The plan combines several targeted drugs that attack cancer cells in different ways, followed by a standard chemotherapy regimen. The main goal is to s…

This study is testing if adding a drug called vorinostat to standard medications can better prevent graft-versus-host disease (GVHD) in children and young adults getting a bone marrow transplant for blood cancers. GVHD is a serious complication where the donor's immune cells atta…

This study is testing a new oral medication called nemtabrutinib for people with advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for a…

This study is testing a two-drug combination for people with certain slow-growing types of B-cell lymphoma who have not yet received treatment. The goal is to see how well the pill ixazomib works when given with the antibody drug rituximab to shrink tumors and control the cancer.…

This study is testing a combination of two drugs, ibrutinib and rituximab, for people with mantle cell lymphoma, a type of blood cancer. It is for two groups: those whose cancer has returned or hasn't responded to prior treatment, and older patients newly diagnosed with the disea…

This study is testing a new type of cell therapy for patients with blood cancers or bone marrow diseases who need a stem cell transplant from a partially matched family donor. The goal is to see if adding specially treated immune cells, called 'veto cells,' can help the donor's c…

This study is testing a two-part treatment approach for younger patients newly diagnosed with mantle cell lymphoma, an aggressive type of blood cancer. First, patients receive a targeted pill (ibrutinib) plus an immunotherapy drug (rituximab) to attack the cancer cells. If they r…

This early-phase study is testing a three-step treatment for people newly diagnosed with a high-risk form of mantle cell lymphoma, a type of blood cancer. First, patients receive two drugs (acalabrutinib and rituximab), followed by an infusion of their own genetically modified im…

This study aims to understand why mantle cell lymphoma, a type of blood cancer, comes back or doesn't respond to initial treatment. Researchers will analyze tissue samples from 160 patients who experienced relapse or resistance after their first round of therapy. By studying thes…